KYPROLIS 60mg powder for solution for infusion AMGEN ORIGINAL MEDICINE
Chemical substance: carfilzomib
ATC code: L01XX45 • Antineoplastic and immunomodulating agents | Other antineoplastic agents
Active substance
Results for the substance carfilzomib
1 result
About this active substance
Carfilzomib is a medication used for the treatment of relapsed or refractory multiple myeloma, a type of bone marrow cancer. It is a proteasome inhibitor that works by blocking the activity of proteasomes, cellular structures responsible for protein degradation.
By inhibiting proteasomes, carfilzomib causes the accumulation of defective proteins in cancer cells, leading to their death. The medication is administered intravenously, usually in combination with other therapies such as dexamethasone or lenalidomide.
Treatment requires close monitoring to assess the patient's response and manage potential side effects. It is important for patients to adhere to the administration schedule and inform their doctor of any unusual symptoms.
Common side effects include fatigue, nausea, fever, shortness of breath, and high blood pressure. In rare cases, more severe complications such as heart failure or liver toxicity may occur. Patients should be regularly monitored to prevent these risks.
By inhibiting proteasomes, carfilzomib causes the accumulation of defective proteins in cancer cells, leading to their death. The medication is administered intravenously, usually in combination with other therapies such as dexamethasone or lenalidomide.
Treatment requires close monitoring to assess the patient's response and manage potential side effects. It is important for patients to adhere to the administration schedule and inform their doctor of any unusual symptoms.
Common side effects include fatigue, nausea, fever, shortness of breath, and high blood pressure. In rare cases, more severe complications such as heart failure or liver toxicity may occur. Patients should be regularly monitored to prevent these risks.